The concept that tau is involved in neurodegenerative diseases is supported by the evidence that tau aggregations and mutations correlate with several neurodegenerative diseases, including AD, FTDP17, PSP, etc. Furthermore, the presence of mutations on tau is adequate to elicit neurological pathology in both human and transgenic animal models [23,24]. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.